Open AccessDendritic cell‐based immunotherapy for prostate cancer
Author(s) -
Tjoa Benjamin A.,
Lodge Patricia A.,
Salgaller Michael L.,
Boynton Alton L.,
Murphy Gerald P.
Publication year - 1999
Publication title -
ca: a cancer journal for clinicians
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 62.937
H-Index - 168
eISSN - 1542-4863
pISSN - 0007-9235
DOI - 10.3322/canjclin.49.2.117
Subject(s) - prostate cancer , immunotherapy , cancer immunotherapy , dendritic cell , medicine , cancer research , cancer , immunology , immune system
Dendritic cells are unique in their ability to stimulate naive T cells. These investigators have developed a prostate cancer vaccine using autologous dendritic cells as a vehicle to present prostate antigens to T cells in vivo.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom